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Abstract 
The primary function of the bronchial epithelium is to act as a defensive barrier aiding 
the maintenance of normal airway function. Bronchial epithelial cells (BECs) form 
the interface between the external environment and the internal milieu, making it a 
major target of inhaled insults. However, BECs can also serve as effectors to initiate 
and orchestrate immune and inflammatory responses by releasing chemokines and 
cytokines, which recruit and activate inflammatory cells. They also produce excess 
reactive oxygen species as a result of an oxidant/antioxidant imbalance which 
contributes to chronic pulmonary inflammation and lung tissue damage. Accumulated 
mucus from hyperplastic BECs obstructs the lumen of small airways, whereas 
impaired cell repair, squamous metaplasia and increased extracellular matrix 
deposition underlying the epithelium is associated with airway remodelling 
particularly fibrosis and thickening of the airway wall. These alterations in small 
airway structure lead to airflow limitation, which is critical in the clinical diagnosis of 
chronic obstructive pulmonary disease (COPD). In this review, we discuss the 
abnormal function of BECs within a disturbed immune homeostatic environment 
consisting of ongoing inflammation, oxidative stress and small airway obstruction.  
We provide an overview of recent insights into the function of the bronchial 
epithelium in the pathogenesis of COPD and how this may provide novel therapeutic 
approaches for a number of chronic lung diseases. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) represents a syndrome comprising 
chronic bronchitis (CB) and emphysema characterised by largely irreversible and 
progressive airflow limitation [1]. More than 200 million people worldwide are 
currently affected by the disease, which is the fourth leading cause of death 
worldwide [2] and is projected to be the third leading cause by 2030 [3]. At the 
pathological level, COPD is associated with chronic pulmonary inflammation in 
response to environmental insults.  This is, in turn, inextricably linked to disturbed 
tissue repair, increased mucus secretion and epithelial cell hyperplasia with airway 
wall thickening in the small conducting airways [4].  Bronchial epithelial cells 
(BECs), which line the airway lumen, are among the first sites of contact for 
environmental stimuli (microorganisms, gases and allergens) and perform a crucial 
role in maintaining normal airway function. Studies on human bronchial biopsies in 
COPD have demonstrated increased inflammatory gene and protein expression and 
structural alterations in bronchial epithelial cells [5–8] suggesting a causal role of 
BECs in COPD pathogenesis. 
 
Bronchial epithelial cells (BECs) 
BECs are composed of various cell types and may be classified into three categories 
based on ultrastructural, functional and biochemical criteria: basal, ciliated and 
secretory cells [9].  Basal cells are ubiquitous in the large (50%) and small airways 
(81%) [10] but the absolute cell count decreases with airway size [11].  Basal 
epithelial cells exclusively express hemidesmosomes indicating an important role in 
the attachment of themselves and more superficial cells to the basement membrane 
[11, 12].  These cells are also thought to be primary progenitor or stem cells because 
they can self-renew and give rise to secretory and ciliated epithelial cells in response 
to epithelial injury [13].  In addition to their structural and progenitor functions, 
basal epithelial cells also produce various bioactive molecules, including neutral 
endopeptidase, 15-lipoxygenase products and cytokines [14].   
Ciliated epithelial cells are the major cell type within the airways, accounting for over 
50% of all epithelial cells [9]. They possess up to 300 cilia per cell and have 
numerous energy-producing mitochondria adjacent to their apical surface, 
highlighting the critical function of the cells in clearing mucus out from the airways 
via directional ciliary beating [15].   
Mucus (goblet) cells are large secretory granules containing large quantities of mucin 
glycoproteins which secrete mucus in order to trap foreign objects in the airway 
lumen [16]. A balance between the correct amount of mucus production and clearance 
provides a critical defensive barrier and prevents airway surface desiccation [17]. 
Mucus cells are also capable of self-renewal and differentiation into ciliated epithelial 
cells [11].  
In humans, non-ciliated secretory cells called Club cells (these were formerly known 
as Clara cells) exist in the small airways and trachea.  These are morphologically 
identified by their distinctive dome-shaped apical protrusions and molecularly 
identified by their expression of Clara cell secretory protein [17]. The cells possess 
several lung protective functions. They regulate bronchiolar epithelial integrity and 
immunity by producing bronchiolar surfactants and specific anti-proteases; they 
metabolise xenobiotic compounds by the action of p450 mono-oxygenases [18] and 
also have an important stem cell function as progenitors for both ciliated and 
mucus-secreting cells [19].  
Considering the critical functions of BECs in maintaining the normal structure and 
function of the airways it is not surprising that dysregulated BECs may contribute to 
the pathogenesis of many lung diseases such as COPD. In this review we address the 
evidence for a critical role of dysfunctional BECs in the pathogenesis of COPD. 
 
BECs initiate and regulate immune responses 
The lungs are persistently exposed to environmental insults, but rarely show signs of 
infection, implying the existence of effective host defence mechanisms. The host is 
protected against various stimuli by a multi-layered defence system consisting of a 
combination of physical barriers, as well as innate and adaptive immune mechanisms 
[20].  The importance of numerous immune cell types in COPD has been stressed for 
many years [21].  Vareille et al. [22] summarised the important functions of BECs in 
response to respiratory viruses and these can be categorised on several different levels. 
Firstly, BECs form an efficient physical barrier function against viral invasion by 
exhibiting cell–cell junctions, including tight junctions, adherens junctions, gap 
junctions and desmosomes [23]. Ciliated and mucus cells together enable the 
formation of a mucus barrier that traps and clears approximately 90% of inhaled 
particles [24]. Secondly, BECs rapidly recognise molecules that are exclusive to 
microbes, namely, pathogen-associated molecular patterns (PAMPs), via expression of 
pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs).  This 
recognition enables BECs to subsequently interact with, guide, activate and modulate 
other immune cells [25]. Thirdly, BECs produce various antiviral substances and 
release chemokines and cytokines that are important in both innate and adaptive 
immune processes upon viral recognition. 
Cigarette smoke (CS) is the main etiological factor for COPD. CS can disturb immune 
homeostasis in the lungs and change airway host defence mechanisms leading to 
COPD [26]. CS induces dramatic alterations in the airway epithelial architecture and 
impairs barrier functions of BECs by increasing the permeability of the airway 
epithelium, impairing cilia beat ability and reducing mucociliary clearance [27, 28]. 
This barrier dysfunction, which is often found in COPD [29, 30], can increase viral 
binding and entry into cells, further impairing barrier function [31–33]. CS also 
inhibits the production of interferons (IFNs), important antiviral substances, by BECs 
upon stimulation with a viral double-stranded RNA mimic, polyI:C [34], indicating 
that BECs have an impaired immune defence against viral infections. 
In addition to the compromised immune barrier function following chronic CS 
exposure, altered BECs also show disproportionate immune responses to other 
environmental hazards. CS and other inhaled toxic agents cause direct damage to 
BECs leading to the release of endogenous molecules called damage-associated 
molecular patterns (DAMPs) [35]. Concentrations of high-mobility group box 1 [36], 
uric acid and extracellular ATP [37], which are important DAMPs, are shown to be 
increased in bronchoalveolar lavage fluid of patients with COPD compared with 
smokers without COPD. Similar to PAMPs, these signals are identified by PRRs, such 
as TLR4 and TLR2 on BECs [38] and can subsequently trigger a non-specific 
inflammatory response [39]. Release of early cytokines and chemokines [such as 
tumour necrosis factor α (TNF-α) and interleukin (IL)-1 and IL-8/CXCL8] by BECs 
elicits the recruitment of macrophages, neutrophils and dendritic cells (DCs) to the 
site of inflammation [40, 41].  These cells, in turn, secrete proteolytic enzymes and 
reactive oxygen species (ROS), causing lung tissue damage [42].  
DCs are specialised antigen-presenting cells that have a central function in the 
initiation of innate and adaptive immune responses [43]. By integrating multiple 
signals from the local microenvironment, DCs promote CD4+ T helper cell 
differentiation and CD8+ cytotoxicity [35], which are both associated with more 
advanced stages of airflow limitation and emphysema in COPD [44]. Considering the 
close proximity of BECs and DCs, DCs are likely to be receptive to local signals 
derived from epithelial cells. Several studies have demonstrated that DC migration, 
maturation and activation is regulated by BEC-secreted chemokines [45, 46]. For 
example, MIP-3α/CCL20, the unique ligand for CCR6 released by BECs in response 
to CS exposure, can facilitate the recruitment of DC subsets to the airway epithelium 
[41, 45]. BECs not only help promote terminal differentiation of B-cells oriented 
towards polymeric immunoglobulin-A (IgA) production by producing different 
cytokines, such as TGF-β, IL-5 or IL-10 [47], but also mediate IgA transportation [48]. 
Thus, we suggest that BECs can both initiate and regulate the innate and adaptive 
immune systems involved in COPD pathogenesis (Figure 1). 
 
BECs act as both targets and potent effector cells in chronic pulmonary 
inflammation 
Chronic inflammation contributes to airflow limitation in COPD [1, 49]. Chronic 
inflammation in COPD is mainly characterised by the accumulation of neutrophils, 
macrophages, B cells and CD8+ T cells, especially in small airways [50]. Various 
inflammatory mediators also have important functions in the pathogenesis of the 
disease. BECs serve as a barrier to noxious stimuli and produce mediators and 
enzymes to maintain normal airway homeostasis. Respiratory viruses rapidly 
stimulate epithelial cells to secrete a wide range of pro-inflammatory mediators, such 
as IL-6, IL-8 and granulocyte-monocyte colony-stimulating factor (GM-CSF) [51, 52]. 
These early activated cells cause changes in endothelial cell physiology and further 
induce migration and infiltration of inflammatory cells to the airways [52–54]. Under 
normal conditions, the inflammatory cells in airways kill and eliminate inhaled 
foreign matter by secreting cytotoxic mediators and proteases, employing 
phagocytosis and a respiratory burst. However, sustained deleterious environmental 
stimuli, such as CS, may cause injury and alterations in defence mechanisms in BECs. 
The bronchial epithelium not only serves as a target of environmental stresses, but 
also works as a major effector to propagate the inflammatory process [55]. BECs 
produce primary inflammatory mediators, such as IFN-γ, TNF-α and IL-1, which then 
trigger the release of secondary mediators by BECs, including other cytokines, lipid 
mediators, growth factors, proteases and ROS [35, 56, 57].  A summary profile of 
the mediators produced by BECs potentially involved in COPD is shown in Table 1, 
with further details on major mediators provided in the following section. 
Lipid mediators, including prostaglandins (PGs), leukotrienes (LTs) and 
platelet-activating factor (PAF), are produced by BECs in response to various stimuli 
[58, 59] and act in an autocrine or paracrine manner to trigger the production of more 
lipid mediators [60, 61]. These mediators are chemotactic for neutrophils and 
macrophages and can alter vascular and epithelial permeability [62]. PAF and LTs can 
induce airway mucin secretion and cause bronchoconstriction [60, 61]. When oxidant 
exposure (e.g., chronic CS exposure) is continuous, oxidant species are especially 
important in the lung epithelium. Reactive species, such as hydrogen peroxide (H2O2), 
superoxide anion radicals (O2●), hydroxyl radicals (i.e., OH●), nitric oxide (NO) and 
peroxynitrite (ONOO), change cell functions in the lungs. The oxidants released by 
BECs [63, 64] either directly injure the airway epithelium or alter the expression and 
activation of redox-sensitive pro-inflammatory signalling pathways including nuclear 
factor-κB (NF-κB) and activation protein (AP)-1 [65], thereby amplifying 
inflammatory cell influx. Cytokines are pluripotent proteins that are produced and 
released by various cell types, including human BECs [66]. Primary pro-inflammatory 
mediators such as IL-1 and TNF-α are produced rapidly by BECs upon stimulation 
and can feedback on the same cells to up-regulate the expression and secretion of 
secondary cytokines including IL-6, IL-8/CXCL8 and GM-CSF [35, 56, 57, 66]. In 
addition, BECs are a major source of numerous chemokines such as CXCL1, CXCL5, 
CXCL10, CCL11, CCL2 and CCL5 [67] which facilitate the recruitment and 
activation of different inflammatory cells within the airways.  These recuited 
inflammatory cells can release various proteases, including neutrophil elastase and 
matrix metalloproteinases (MMPs), which break down connective tissue components, 
particularly elastin, in lung parenchyma to produce emphysema. 
Exposure of BECs to cigarette smoke results in the activation of numerous 
redox-associated intracellular signalling pathways including MAPKs, NF-κB and 
AP-1 [68, 69]. Other transcription factors, including cAMP response element-binding 
protein, CBP [70], CCAAT/enhancer-binding protein-b [71] and peroxisome 
proliferator-activated receptor [72], are also activated by CS exposure. These all 
contribute to varying degress to the expression of inflammatory mediators in BECs. 
 
BECs contribute to the oxidant/antioxidant imbalance in oxidative stress 
Increasing evidence showed that oxidative stress is an important feature in COPD [73, 
74] because of excess ROS in the antioxidant defence mechanisms in the airways. 
BECs can produce increased amounts of ROS in response to different stimuli [75]. 
The airways are exposed to exogenous oxidants, such as CS, which summate with 
endogenous ROS production to elevate oxidative stress and further increase the 
inflammatory and destructive response in COPD. 
Activation of MAPK and NF-κB pathways [68, 76] and increased cytokine release 
[77] has also been demonstrated in airway epithelial cells in response to oxidant stress 
per se and this may be linked, at least in part, to alterations in the histone 
acetylation/deacetylation balance [78, 79]. The increased expression and release of 
mediators, such as CXCL8/IL-8, GM-CSF, soluble ICAM-1 and TNF-α, may also 
regulate the influx of inflammatory cells [80]. For instance, exposure of human 
airway epithelial cells to ozone results in the induction of adhesion molecules on 
BECs leading to increased neutrophil adhesion [81]. Therefore, oxidative stress in 
BECs may amplify the ongoing inflammatory responses in COPD. In addition, 
oxidative stress can increase both airway mucus obstruction in vivo and the expression 
of mucin genes (MUC5AC) in vitro by activating epidermal growth factor receptors 
(EGFRs) in BECs [82, 83]. The activation of EGFR also mediates oxidative stress 
induced-proliferation of BECs [84].  
Oxidative stress causes direct injury of BECs. Ozone alters the distribution of β1 
integrins in cultured primate BECs resulting in damage of cells and loss of cilia [85].  
Exposure of BECs to oxidants increases their permeability and can result in apoptosis 
or necrosis [86, 87]. These effects may be attributed to DNA strand breaks in airway 
epithelial cells that induce changes in the expression of epithelial cell-specific genes 
[88]. These injuries to BECs impair their protective capacity against inhaled oxidants 
and other insults, enhancing local inflammation and cell death. 
Numerous endogenous antioxidants are produced to maintain oxidant/antioxidant 
homeostasis in the airways. Glutathione (GSH) is a major antioxidant in airway 
epithelial cells and in epithelial lining fluid, but the concentration of GSH in the latter 
is much higher than that in the former [89, 90]. Extracellular glutathione peroxidase 
can be released by BECs and macrophages particularly in response to CS or oxidative 
stress [91]. GSH and its redox system can inactivate H2O2, O2●- and reactive nitrogen 
species [90] and are important for the detoxification of lipid peroxides or other toxic 
metabolites in lung tissue.  Oxidative stress induced by hyperoxia, H2O2, menadione 
or ozone exposure in vivo in rats and monkeys, may initially deplete GSH although 
this is followed by a significant increase in GSH levels.  Similar results are seen in 
vitro in human BECs which was associated with the tolerance of cells to further 
oxidative stress [92, 93]. However, Rusznak et al. [94] demonstrated that exposure to 
CS leads to a significant decrease in intracellular GSH levels without a rebound 
increase in levels within primary cultures of human BECs derived from healthy 
never-smokers, smokers with normal pulmonary function and those with COPD. 
Furthermore, Van der Toorn M et al. [95] showed that CS irreversibly modifies GSH, 
thereby depleting the total available GSH pool in airway epithelial cells. These 
findings indicated a chronic lack of protection against oxidative stress, providing a 
mechanism by which BECs contribute to CS-induced oxidative damage found in 
patients with COPD (Figure 2). 
 
Goblet cell hyperplasia and mucous metaplasia results in CB in COPD 
Mucus is a liquid bilayer that lines the inner surface of the airways and exists as the 
first line of defence against various insults. Inhaled particles are trapped in viscous, 
adhesive liquid gel and removed from the airways by mucociliary clearance [96]. The 
efficiency of mucociliary transport depends on the viscoelasticity of mucus, which is 
conferred by mucous glycoproteins or mucins [97]. Mucins are produced and secreted 
by several cell types and seromucous glands in the submucosa. Among these cell 
types, goblet cells have the greatest potential for mucus composition [198, 99]. 
Chronic bronchitis (CB) is one of the two major diseases constituting COPD. CB is 
caused by excessive luminal mucus resulting from a combination of mucus 
hypersecretion by goblet cells and decreased mucus elimination. Smokers with CB 
have increased numbers of goblet cells, which are associated with elevated amounts 
of intracellular mucin, in which MUC5AC is predominant form, compared with 
non-smoking controls [100, 101]. The hypersecreted mucus with increased viscosity 
and decreased antibacterial products aggravates airflow limitation and leads to an 
increased risk of chest infection [98, 102]. 
Inflammation, oxidative stress and proteases involved in COPD pathogenesis have 
been linked to goblet cell hyperplasia accompanied with hypersecretion of mucins. 
Various inflammatory mediators and signalling pathways regulate the transcription of 
MUC genes.  IL-1β, IL-17A and TNF-α induce mucus production via the activation 
and nuclear translocation of NF-κB [103, 104]. IL-1β-induced MUC5AC expression 
also depends on cyclooxygenase (COX)-2-generated PGE2 and triggering of a cyclic 
AMP-protein kinase A-dependent pathway through PGE receptors (EPs), specifically 
EP2 and EP4 receptors [105]. Up-regulation of chloride channels expressed in BECs 
increases Cl- secretion and regulates mucus volume [106]. IL-13 can also induce 
mucin gene expression in human BEC cultures through the MAPK and 
phosphatidylinositol 3-kinase pathways [107]. IL-13 also induces disordered mucus 
cell metaplasia via EGFR activation in COPD [108]. Oxidative stress, both 
exogenously from CS and endogenously from neutrophils, can activate EGFR and 
induce mucin synthesis [109]. Furthermore, a recent study reported that human BECs 
express the arylhydrocarbon receptor (AhR) whose activation causes excess mucin 
production in a ROS-dependent manner [110]. Furthermore, human neutrophil 
elastase [111], MMP-9 [112] and MMP-14 [113] also increase mucin production via 
an EGFR-mediated mechanism. 
Failure to clear mucus from the airway surface is another critical event in the 
pathogenesis of CB. Excess mucin production leads to an imbalance of mucin, salt 
and water on the airway surface, resulting in mucus stasis and reduced clearance, 
which may be attributed to two mechanisms. One is the reduced ciliary beat efficiency 
due to the increased viscosity of the periciliary liquid layer (PCL) which underlies the 
mucus layer and acts as a lubricant. The other is that the depleted PCL, flattened cilia 
and adhesion of the thickened mucus to the apical cell surface contribute to the failure 
of cough-dependent clearance [114]. 
   
Disordered repair, regeneration and consequent remodelling of airways actively 
contribute to airflow limitation in COPD 
In addition to mucus accumulation in airway lumen, airflow obstruction is also 
associated with small airway remodelling in COPD [115]. Thickening of airway wall 
tissue associated with BEC repair, squamous metaplasia and increased amounts of 
extracellular matrix (ECM) deposition are characteristic features of airway 
remodelling in COPD. Acute exposure to inhaled toxic insults, such as CS or 
microorganisms, induces the loss of epithelial integrity and increased epithelial injury. 
Under normal conditions this injury is repaired or the epithelium regenerated as 
exemplified in several animal models by the proliferation and migration of the basal 
epithelial cells neighbouring the wound over the provisional ECM secreted by 
epithelial cells, squamous metaplasia, progressive redifferentiation and finally 
ciliogenesis and complete regeneration of a pseudostratified secretory or ciliated 
epithelium [116, 117]. This repair and regeneration “ad integrum” leaves no residual 
trace of the previous injury. However, any delay or interruption in the epithelial repair 
and redifferential process caused by interactions with other cells or the presence of 
inflammatory mediators may disturb the normal repair and regeneration process 
leading to ECM deposition and airway fibrosis. 
Peripheral airway wall fibrosis is more prevalent in COPD compared with asthma and 
represents an important cause of airway narrowing in COPD [118, 119]. Chronic 
exposure to CS or environmental pollution induces the loss of epithelial integrity, 
leading to epithelial abnormalities which can affect airway tissue fibrosis.  The loss 
of epithelial integrity impairs the innate immune functions of the airway epithelium 
[120, 121] and extensive molecular reprogramming allows mesenchymal 
transdifferentiation into fibroblasts by a process called epithelial-mesenchymal 
transition (EMT) [122].  Zhang et al. [123] demonstrated that EMT occurs in human 
BECs stimulated by TGF-β1. Furthermore, Sohal et al. [124] reported that EMT may 
be an active process in COPD airways. This process is accompanied with progressive 
loss of epithelial markers, gain in migratory and invasive potential and elevated 
ability to produce ECM components [125, 126] which all contribute to airway wall 
fibrosis and thickening. In addition, BECs can produce and release various 
inflammatory mediators and growth factors including TGF-β [50] which is the main 
stimulus causing fibroblasts to produce ECM constituents.  MMPs, expressed by 
migrating epithelial cells, have key functions in the migration of BECs (MMP-9), the 
shift from an epithelial to a mesenchymal phenotype (MMP-3 and MMP-11) and 
degradation of ECM components during the tissue remodelling process (MMP-12) 
[127, 128]. Thus, COPD epithelial cells produce abnormal levels of active MMPs. 
Dysregulated production and activation of MMPs will result in an imbalance of ECM 
turnover and induce degradation in lung parenchyma and deposition in bronchi and 
bronchioles in COPD [128–130]. 
 
Conclusions and future directions 
CODP is characterised by airflow limitation that is not fully reversible because of 
remodelling of the small airway compartment and emphysematous destruction of the 
parenchyma [131]. Several mechanisms have been implicated in the pathogenesis of 
the disease, including immune dysregulation, exaggerated chronic inflammation and 
oxidant and antioxidant imbalance in response to inhaled insults. As the first line of 
defence against noxious insults, the human bronchial epithelium lining the respiratory 
airways exerts a negative regulatory function in the preventing the onset of COPD. 
Upon repeated environmental challenge, BECs serve as a switchboard to initiate and 
orchestrate immune responses through the release of chemokines and cytokines, 
which recruit and activate inflammatory cells. Epithelial cells damaged by inhaled 
agents, such as CS, produce a disorganised immune response and heightened 
inflammatory processes.  Exposure of BECs to CS, inhaled airborne pollutants or 
other oxidants not only generates excess ROS but also impairs antioxidant gene 
expression in BECs [75, 94, 95] leading to an oxidant/antioxidant imbalance and lung 
inflammation. In addition, goblet cell hyperplasia, mucus accumulation, squamous 
epithelial metaplasia, airway wall fibrosis and thickening caused by ECM deposition 
underlying the epithelium are major characteristics of COPD and can cause small 
airway obstruction and airflow limitation. 
Even after smoking cessation in COPD patients, oxidative stress and pulmonary 
inflammation persist, which may hamper or prevent tissue repair [35]. Therefore, an 
effective treatment regime for COPD requires stopping exposure to toxic substrates, 
such as CS, as well as inhibition of excessive inflammation, oxidative stress and 
ideally reversal of structural changes within the small airways and parenchyma [132].  
Considering the ability of BECs to orchestrate the myriad of downstream responses to 
cigarette smoke, drugs that modify the ability of activated COPD BECs to modulate 
these oxidative stress, immune responses and inflammatory processes should be 
effective in COPD.  A consequence of preferentially targeting BECs is that 
downstream effects on inflammatory cell recruitment and on airway remodelling 
should also be improved without the need for separate therapies.
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Table 1.  Mediators produced by BECs in COPD. 
 
Lipid mediators PGE2, LTs B4 and C4, PAF 
Reactive oxygen species (and 
products) 
H2O2, superoxide anion radicals, hydroxyl 
radicals, nitric oxide, peroxynitrite, 
8-isoprostanes, 3-nitrotyrosine 
Cytokines  Proinflammatory IL-1β, TNF-α, IL-6, IL-8, GM-CSF 
           T-helper IL-4, IL-9, IL-10, IL-13 (T-helper-2); IFN-γ (T-helper-1) 
Chemokines    CXC IL-8 (CXCL8), GRO-α (CXCL1), ENA-78 (CXCL5), IP-10 (CXCL10) 
                CC MCP-1 (CCL2),  RANTES (CCL5), eotaxin (CCL11) 
Growth factors TGFβ, Endothelin-1, PDGF, VEGF, EGF 
Proteases MMP-1, -2, -7, -9, -12, Cathepsins, Cysteine proteinases 
 
PDGF: Platelet-derived growth factor; VEGF: Vascular endothelial growth factor; 
EGF: Epidermal growth factor 
 
 
Figure legends. 
 
 
 
Figure 1. Bronchial epithelial cells (BECs) initiate and control immune and 
inflammatory responses in COPD pathogenesis 
Cigarette smoke activates BECs by triggering pattern recognition receptors (PRR) 
such as Toll-like receptors (TLRs) either directly by cigarette components or 
indirectly via the release of damage-associated molecular patterns (DAMPs). On 
activation, BECs release pro-inflammatory cytokines and chemokines, which recruit 
infiltrating inflammatory cells including macrophages, neutrophils and dendritic cells 
(DCs). Activated immune cells, in turn, secrete additional inflammatory mediators, 
reactive oxygen species (ROS) and proteolytic enzymes (neutrophil elastase [NE] and 
matrix metalloproteinases [MMPs]).  These mediators contribute to the airway 
remodelling and destruction of lung tissue that is involved in the pathogenesis of 
COPD. HSP=heat shock protein. HMGB1=high-mobility group box 1  
 
 
 
 
Figure 2.  Bronchial epithelial cells (BECs) contribute to oxidative 
stress-mediated lung inflammation.  
BECs are exposed to exogenous oxidants, such as CS, which induces production of 
ROS and depletion of some antioxidants. Excessive ROS production overwhelms the 
antioxidant defense mechanisms in the airways resulting in elevated expression of 
inflammatory mediators.  This, in turn, induces an influx of inflammatory cells into 
the airway and lung. In addition, excess oxidative stress impairs the structural 
integrity of BECs and the protective capacity of the bronchial epithelium against 
inhaled oxidants, further enhancing the inflammation. 
